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Background
Ipilimumab is the first agent approved for the treatment
of advanced melanoma that showed a survival benefit in
randomized phase 3 trials. Despite the survival benefit,
due to its mechanism of action it is associated with a
slow onset and low rate of responses and, in many
cases, responses occur after other therapies, like che-
motherapy, targeted therapy and radiotherapy. Electro-
chemotherapy (ECT) has been shown to be effective and
well tolerated for local control of metastatic melanoma
with superficial lesions. The current challenge is to
improve ipilimumab efficacy by combination/sequence
with other therapies. We performed a pilot study of
combination with ipilimumab and ECT in order to ver-
ify the possible increase of response rate. Furthermore,
due to the lack of predictive markers, we evaluated the
possible predictive role of circulating T-regulatory cells
(T-Reg) variations in peripheral blood mononuclear cells
(PBMC) of treated patients.
Methods
We collected data from 15 patients (pts) with advanced
melanoma (9 stage IIIc and 6 stage IV M1c) treated with
ipilimumab at 3 mg/kg every 3 weeks for 4 cycles (day 1)
and ECT with bleomycine at 15 mg/m2 (day 2) on superfi-
cial lesions. Blood draws were collected on day 0, 1 and 2,
then on day 15 and 30 from ECT, at each cycle of ipilimu-
mab and at every tumor evaluation (every 12 weeks).
PBMC were thawed and labeled with anti-CD4-Pe-Cy-5,
CD25-Pe and anti-FoxP3-AlexaFlour488 for T-Reg.
Results
10/15 (67%) pts showed local objective responses (4 CR
and 6 PR). 7/10 (70%) pts showed local response (6 PR
and 1 CR) after the second ipilimumab dose and 3/10
showed response (3 CR) at week 12. Two pts with PR
(28%) out of the group of 7 showed response on distant
lesions at week 24 (abscopal effect). All pts are still alive
with a median follow up of 12.4 months (range 6-18).
We found in all responders a decrease of T-Reg of 0.10%
(range 0.50-2.6%) per cycle and no variation of CD4+ and
CD25+ lymphocytes. Furthermore 5/15 pts not responders
had a delayed stable disease (local and distant) at week 16,
with no variations of T-Regs.
Conclusion
Our preliminary results show that a combination approach
with ipilimumab and ECT may increase responses to ipili-
mumab. T-Reg decrease in PBMC could be associated
with early response to treatment. Further studies about
this combination are warranted.
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